EFFECT OF PHOSPHOLIPID COMPOSITION OF RECONSTITUTED HDL ON ITS CHOLESTEROL EFFLUX AND ANTI-INFLAMMATORY PROPERTIES
The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β HDL, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines TNF-α, IL-1β, and/or IL-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed.
1 . A pharmaceutical formulation comprising the apolipoprotein mimetic peptide 5A of SEQ ID NO:1 and at least one phospholipid.
2 . The pharmaceutical formulation of claim 1 , wherein said at least one phospholipid is a phospholipid selected from the group consisting of sphingomyelin (SM), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and a combination thereof.
3 . The pharmaceutical formulation of claim 1 , wherein said at least one phospholipid is sphingomyelin (SM).
4 . The pharmaceutical formulation of claim 1 , wherein said at least one phospholipid is 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).
5 . The pharmaceutical formulation of claim 1 , wherein said molar ratio of peptide to phospholipid is 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.
6 . The pharmaceutical formulation of claim 1 , wherein said molar ratio of peptide to phospholipid is 1:7.
7 . The pharmaceutical formulation of claim 1 , wherein said peptide is complexed with said at least one phospholipid.
8 . The pharmaceutical formulation of claim 1 , wherein said formulation is lyophilized.
9 . The pharmaceutical formulation of claim 1 , wherein said formulation has a pH of 5 to 7.
10 . The pharmaceutical formulation of claim 1 , wherein said formulation has a pH of is about 5, 5.5, 6, 6.5, or 7.
11 . A method for generating a pharmaceutical formulation according to claim 1 , wherein said method comprises mixing of said peptide with said at least one phospholipid, wherein said mixing occurs at a pH of 5 to 7.
12 . The method of claim 11 , wherein said pH is about 5, 5.5, 6, 6.5, or 7.
13 . The method of claim 11 , wherein said peptide and said at least one phospholipid are mixed at a molar ratio of peptide to phospholipid of 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.
14 . The method of claim 11 , wherein said molar ratio of peptide to phospholipid during mixing is 1:7.
15 . The method of claim 11 , wherein said method further comprises a step of lyophilization.
16 . The method of claim 11 , wherein said method generates a high-density lipoprotein-like complex.
17 . A method of treating a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 .
18 . A method of increasing cholesterol efflux in a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 .
19 . A method of treating a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 , wherein said pharmaceutical formulation exhibits anti-atherosclerotic activity.
20 . A method of increasing pre-β HDL in a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 .
21 . A method of treating a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 , wherein said pharmaceutical formulation exhibits anti-inflammatory activity.
22 . A method of treating a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 , wherein said pharmaceutical formulation inhibits cytokine release.
23 . The method of claim 22 , wherein said cytokines are selected from the group consisting of TNF-α, IL-1β, IL-6, and a combination thereof.
24 . A method of increasing cholesterol mobilization and/or esterification in a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 .
25 . A method of inducing atherosclerosis regression in a subject in need thereof comprising administering a pharmaceutical formulation according to claim 1 .
26 . A method according to claim 11 , comprising administering an additional agent before, after or concurrently with the pharmaceutical formulation.